Scroll

vandetanib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
angiogenesis inhibitors	4178	443913-73-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ZD-6474 vandetanib zactima caprelsa ZD6474	In vitro studies have shown that vandetanib inhibits the tyrosine kinase activity of the EGFR and VEGFR families, RET, BRK, TIE2, and members of the EPH receptor and Src kinase families. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment. In addition, the N-desmethyl metabolite of the drug, representing 7 to 17.1% of vandetanib exposure, has similar inhibitory activity to the parent compound for VEGF receptors (KDR and Flt-1) and EGFR. In vitro, vandetanib inhibited epidermal growth factor (EGF)-stimulated receptor tyrosine kinase phosphorylation in tumor cells and endothelial cells and VEGF-stimulated tyrosine kinase phosphorylation in endothelial cells. In vivo, vandetanib administration reduced tumor cell-induced angiogenesis, tumor vessel permeability, and inhibited tumor growth and metastasis in mouse models of cancer. Molecular weight: 475.36 Formula: C22H24BrFN4O2 CLOGP: 5.69 LIPINSKI: 1 HAC: 6 HDO: 1 TPSA: 59.51 ALOGS: -4.67 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ZD-6474
vandetanib
zactima
caprelsa
ZD6474

In vitro studies have shown that vandetanib inhibits the tyrosine kinase activity of the EGFR and VEGFR families, RET, BRK, TIE2, and members of the EPH receptor and Src kinase families. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment. In addition, the N-desmethyl metabolite of the drug, representing 7 to 17.1% of vandetanib exposure, has similar inhibitory activity to the parent compound for VEGF receptors (KDR and Flt-1) and EGFR. In vitro, vandetanib inhibited epidermal growth factor (EGF)-stimulated receptor tyrosine kinase phosphorylation in tumor cells and endothelial cells and VEGF-stimulated tyrosine kinase phosphorylation in endothelial cells. In vivo, vandetanib administration reduced tumor cell-induced angiogenesis, tumor vessel permeability, and inhibited tumor growth and metastasis in mouse models of cancer.

Molecular weight: 475.36
Formula: C22H24BrFN4O2
CLOGP: 5.69
LIPINSKI: 1
HAC: 6
HDO: 1
TPSA: 59.51
ALOGS: -4.67
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.30	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Hosey CM, Chan R, Benet LZ
S (Water solubility)	0.01 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Feb. 16, 2012	EMA	GENZYME EUROPE BV
April 6, 2011	FDA	IPR PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Electrocardiogram QT prolonged	150.65	34.55	55	1401	59475	63428091
Reflux gastritis	86.03	34.55	16	1440	1179	63486387
Hypophosphataemia	67.10	34.55	20	1436	11406	63476160
Facial paralysis	63.03	34.55	20	1436	14021	63473545
Lymphocyte count decreased	61.93	34.55	24	1432	30233	63457333
Ataxia	61.48	34.55	20	1436	15175	63472391
Blood triglycerides increased	61.11	34.55	19	1437	12469	63475097
Myoclonus	60.63	34.55	20	1436	15848	63471718
Hypophagia	54.20	34.55	22	1434	31237	63456329
Hemiparesis	53.13	34.55	20	1436	23262	63464304
Ocular hyperaemia	51.63	34.55	20	1436	25124	63462442
Flatulence	45.41	34.55	20	1436	34682	63452884
Neutrophil count decreased	44.65	34.55	23	1433	56383	63431183
Malignant neoplasm progression	44.34	34.55	26	1430	82095	63405471
Disease progression	44.06	34.55	30	1426	122728	63364838
Abdominal distension	37.96	34.55	24	1432	86591	63400975
Metastases to liver	35.42	34.55	15	1441	23624	63463942

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Electrocardiogram QT prolonged	79.31	34.95	29	591	40923	34915388
Blood calcitonin increased	49.82	34.95	6	614	25	34956286
Diarrhoea	43.58	34.95	43	577	389869	34566442
Acne	37.67	34.95	12	608	11054	34945257

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Electrocardiogram QT prolonged	173.33	32.29	70	1936	90316	79652066
Reflux gastritis	83.82	32.29	16	1990	1233	79741149
Myoclonus	54.79	32.29	22	1984	27638	79714744
Hypophosphataemia	54.34	32.29	20	1986	19893	79722489
Blood calcitonin increased	53.38	32.29	7	1999	43	79742339
Facial paralysis	53.23	32.29	20	1986	21052	79721330
Diarrhoea	52.47	32.29	85	1921	880404	78861978
Ataxia	49.88	32.29	20	1986	25019	79717363
Blood triglycerides increased	49.65	32.29	19	1987	21021	79721361
Lymphocyte count decreased	49.43	32.29	24	1982	47265	79695117
Ocular hyperaemia	47.58	32.29	20	1986	28186	79714196
Flatulence	45.60	32.29	22	1984	42702	79699680
Malignant neoplasm progression	45.44	32.29	33	1973	135957	79606425
Acne	44.93	32.29	19	1987	27171	79715211
Hypophagia	44.35	32.29	22	1984	45345	79697037
Hemiparesis	44.14	32.29	20	1986	33713	79708669
Hypertension	43.05	32.29	47	1959	330945	79411437
Metastases to liver	40.92	32.29	18	1988	28296	79714086
Metastases to bone	40.13	32.29	17	1989	24410	79717972

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01EX04	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Other protein kinase inhibitors
FDA MoA	N0000175076	Protein Kinase Inhibitors
FDA EPC	N0000175605	Kinase Inhibitor
FDA MoA	N0000185503	P-Glycoprotein Inhibitors
FDA MoA	N0000187061	Organic Cation Transporter 2 Inhibitors
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:38637	tyrosine kinase inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Medullary thyroid carcinoma	indication	255032005	DOID:3973
Carcinoma of thyroid	indication	448216007
Hypocalcemia	contraindication	5291005
Torsades de pointes	contraindication	31722008
Hypertensive disorder	contraindication	38341003	DOID:10763
Hypothyroidism	contraindication	40930008	DOID:1459
Hypokalemia	contraindication	43339004
Heart failure	contraindication	84114007	DOID:6000
Prolonged QT interval	contraindication	111975006
Hypomagnesemia	contraindication	190855004
Impaired renal function disorder	contraindication	197663003
Interstitial lung disease	contraindication	233703007	DOID:3082
Cerebral ischemia	contraindication	287731003
Pregnancy, function	contraindication	289908002
Severe diarrhea	contraindication	409587002
Breastfeeding (mother)	contraindication	413712001
Congenital long QT syndrome	contraindication	442917000
Posterior reversible encephalopathy syndrome	contraindication	450886002
Significant Bleeding	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.58	Basic
pKa2	5.88	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Proto-oncogene tyrosine-protein kinase receptor Ret	Kinase	P07949	RET_HUMAN	INHIBITOR	Kd	7.85	CHEMBL	CHEMBL
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN	INHIBITOR	Kd	8.32	CHEMBL	CHEMBL
Vascular endothelial growth factor receptor 2	Kinase	P35968	VGFR2_HUMAN	INHIBITOR	Kd	6.33	CHEMBL	CHEMBL
Tyrosine-protein kinase ABL1	Kinase	P00519	ABL1_HUMAN		Kd	8.05	CHEMBL
Mast/stem cell growth factor receptor Kit	Kinase	P10721	KIT_HUMAN		Kd	7.47	CHEMBL
Breakpoint cluster region protein	Kinase	P11274	BCR_HUMAN		Kd	6.06	CHEMBL
Proto-oncogene tyrosine-protein kinase Src	Kinase	P12931	SRC_HUMAN	INHIBITOR	Kd	7.15	CHEMBL
Tyrosine-protein kinase Lck	Kinase	P06239	LCK_HUMAN		Kd	7.77	CHEMBL
Tyrosine-protein kinase Yes	Kinase	P07947	YES_HUMAN		Kd	6.92	CHEMBL
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		Kd	6.44	CHEMBL
Ephrin type-A receptor 2	Kinase	P29317	EPHA2_HUMAN	INHIBITOR	Kd	5.96	CHEMBL
Receptor-type tyrosine-protein kinase FLT3	Kinase	P36888	FLT3_HUMAN		Kd	6.72	CHEMBL
Vascular endothelial growth factor receptor 1	Kinase	P17948	VGFR1_HUMAN	INHIBITOR	Kd	6.59	CHEMBL
Vascular endothelial growth factor receptor 3	Kinase	P35916	VGFR3_HUMAN	INHIBITOR	Kd	6.52	CHEMBL
Macrophage colony-stimulating factor 1 receptor	Kinase	P07333	CSF1R_HUMAN		Kd	5.92	CHEMBL
Platelet-derived growth factor receptor alpha	Kinase	P16234	PGFRA_HUMAN		Kd	6.64	CHEMBL
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN	INHIBITOR	Kd	5.59	CHEMBL
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Kinase	P15735	PHKG2_HUMAN		Kd	5.10	CHEMBL
Fibroblast growth factor receptor 3	Kinase	P22607	FGFR3_HUMAN		Kd	6.62	CHEMBL
Tyrosine-protein kinase HCK	Kinase	P08631	HCK_HUMAN		Kd	6.44	CHEMBL
Receptor tyrosine-protein kinase erbB-4	Kinase	Q15303	ERBB4_HUMAN	INHIBITOR	Kd	6.32	CHEMBL
Rho-associated protein kinase 2	Kinase	O75116	ROCK2_HUMAN		Kd	5.44	CHEMBL
Tyrosine-protein kinase CSK	Kinase	P41240	CSK_HUMAN		Kd	5.60	CHEMBL
Angiopoietin-1 receptor	Kinase	Q02763	TIE2_HUMAN	INHIBITOR	Kd	6	CHEMBL
Ephrin type-A receptor 8	Kinase	P29322	EPHA8_HUMAN	INHIBITOR	Kd	7.04	CHEMBL
Hepatocyte growth factor receptor	Kinase	P08581	MET_HUMAN		Kd	5.39	CHEMBL
Tyrosine-protein kinase Lyn	Kinase	P07948	LYN_HUMAN		Kd	6.96	CHEMBL
5'-AMP-activated protein kinase catalytic subunit alpha-1	Kinase	Q13131	AAPK1_HUMAN		Kd	5.52	CHEMBL
Fibroblast growth factor receptor 1	Kinase	P11362	FGFR1_HUMAN		Kd	6.25	CHEMBL
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform	Kinase	Q16816	PHKG1_HUMAN		Kd	5.96	CHEMBL
Serine/threonine-protein kinase 10	Kinase	O94804	STK10_HUMAN		Kd	7.09	CHEMBL
Serine/threonine-protein kinase PLK4	Kinase	O00444	PLK4_HUMAN		Kd	6.21	CHEMBL
Aurora kinase C	Kinase	Q9UQB9	AURKC_HUMAN		Kd	5.82	CHEMBL
Abelson tyrosine-protein kinase 2	Kinase	P42684	ABL2_HUMAN		Kd	7.16	CHEMBL
Ephrin type-A receptor 5	Kinase	P54756	EPHA5_HUMAN	INHIBITOR	Kd	6.62	CHEMBL
Ephrin type-A receptor 4	Kinase	P54764	EPHA4_HUMAN	INHIBITOR	Kd	5.80	CHEMBL
Fibroblast growth factor receptor 2	Kinase	P21802	FGFR2_HUMAN		Kd	5.96	CHEMBL
Ephrin type-A receptor 6	Kinase	Q9UF33	EPHA6_HUMAN	INHIBITOR	Kd	7.30	CHEMBL
TRAF2 and NCK-interacting protein kinase	Kinase	Q9UKE5	TNIK_HUMAN		Kd	5.64	CHEMBL
Casein kinase I isoform epsilon	Kinase	P49674	KC1E_HUMAN		Kd	5.82	CHEMBL
Tyrosine-protein kinase Fgr	Kinase	P09769	FGR_HUMAN		Kd	6.57	CHEMBL
ALK tyrosine kinase receptor	Kinase	Q9UM73	ALK_HUMAN		Kd	5.68	CHEMBL
Ephrin type-A receptor 3	Kinase	P29320	EPHA3_HUMAN	INHIBITOR	Kd	5.74	CHEMBL
Tyrosine-protein kinase FRK	Kinase	P42685	FRK_HUMAN		Kd	6.77	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5	Kinase	Q9Y4K4	M4K5_HUMAN		Kd	6.35	CHEMBL
Mitogen-activated protein kinase kinase kinase 4	Kinase	Q9Y6R4	M3K4_HUMAN		Kd	5.52	CHEMBL
Cyclin-G-associated kinase	Kinase	O14976	GAK_HUMAN		Kd	7.07	CHEMBL
Receptor-interacting serine/threonine-protein kinase 2	Kinase	O43353	RIPK2_HUMAN		Kd	8.34	CHEMBL
Ephrin type-B receptor 1	Kinase	P54762	EPHB1_HUMAN	INHIBITOR	Kd	6.54	CHEMBL
Ephrin type-A receptor 7	Kinase	Q15375	EPHA7_HUMAN	INHIBITOR	Kd	5.62	CHEMBL
STE20-like serine/threonine-protein kinase	Kinase	Q9H2G2	SLK_HUMAN		Kd	7.02	CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 2	Kinase	Q9HBH9	MKNK2_HUMAN		Kd	5.77	CHEMBL
Epithelial discoidin domain-containing receptor 1	Kinase	Q08345	DDR1_HUMAN		Kd	7.96	CHEMBL
Ephrin type-B receptor 4	Kinase	P54760	EPHB4_HUMAN	INHIBITOR	Kd	6.28	CHEMBL
Serine/threonine-protein kinase receptor R3	Kinase	P37023	ACVL1_HUMAN		Kd	6.33	CHEMBL
Activin receptor type-1	Kinase	Q04771	ACVR1_HUMAN		Kd	6.82	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 1	Kinase	Q02750	MP2K1_HUMAN		Kd	5.74	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 2	Kinase	P36507	MP2K2_HUMAN		Kd	5.96	CHEMBL
Protein-tyrosine kinase 6	Kinase	Q13882	PTK6_HUMAN	INHIBITOR	Kd	7.48	CHEMBL
Tyrosine-protein kinase BTK	Kinase	Q06187	BTK_HUMAN		Kd	5.77	CHEMBL
Tyrosine-protein kinase receptor UFO	Kinase	P30530	UFO_HUMAN		Kd	6.60	CHEMBL
Tyrosine-protein kinase receptor TYRO3	Kinase	Q06418	TYRO3_HUMAN		Kd	7.03	CHEMBL
Ephrin type-B receptor 2	Kinase	P29323	EPHB2_HUMAN	INHIBITOR	Kd	6.36	CHEMBL
Cyclin-dependent kinase 7	Kinase	P50613	CDK7_HUMAN		Kd	5.39	CHEMBL
Ribosomal protein S6 kinase beta-1	Kinase	P23443	KS6B1_HUMAN		Kd	5.80	CHEMBL
Ribosomal protein S6 kinase alpha-6	Kinase	Q9UK32	KS6A6_HUMAN		Kd	6.62	CHEMBL
Mitogen-activated protein kinase kinase kinase MLT	Kinase	Q9NYL2	MLTK_HUMAN		Kd	5.29	CHEMBL
Tyrosine-protein kinase receptor Tie-1	Kinase	P35590	TIE1_HUMAN		Kd	5.82	CHEMBL
Tyrosine-protein kinase TXK	Kinase	P42681	TXK_HUMAN		Kd	5.43	CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 1	Kinase	Q9BUB5	MKNK1_HUMAN		Kd	6.44	CHEMBL
Serine/threonine-protein kinase SIK2	Kinase	Q9H0K1	SIK2_HUMAN		Kd	6.37	CHEMBL
Serine/threonine-protein kinase 33	Kinase	Q9BYT3	STK33_HUMAN		Kd	5.85	CHEMBL
Serine/threonine-protein kinase TNNI3K	Kinase	Q59H18	TNI3K_HUMAN		Kd	5.55	CHEMBL
Discoidin domain-containing receptor 2	Kinase	Q16832	DDR2_HUMAN		Kd	6.49	CHEMBL
Chaperone activity of bc1 complex-like, mitochondrial	Kinase	Q8NI60	COQ8A_HUMAN		Kd	5.35	CHEMBL
Serine/threonine-protein kinase MRCK gamma	Kinase	Q6DT37	MRCKG_HUMAN		Kd	5.66	CHEMBL
Leukocyte tyrosine kinase receptor	Kinase	P29376	LTK_HUMAN		Kd	6.26	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1	Kinase	Q92918	M4K1_HUMAN		Kd	5.26	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 3	Kinase	Q8IVH8	M4K3_HUMAN		Kd	5.82	CHEMBL
Tyrosine-protein kinase Blk	Kinase	P51451	BLK_HUMAN		Kd	7.18	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4	Kinase	O95819	M4K4_HUMAN		Kd	5.85	CHEMBL
Tyrosine-protein kinase Mer	Kinase	Q12866	MERTK_HUMAN		Kd	5.85	CHEMBL
Serine/threonine-protein kinase MRCK alpha	Kinase	Q5VT25	MRCKA_HUMAN		Kd	5.59	CHEMBL
Serine/threonine-protein kinase MRCK beta	Kinase	Q9Y5S2	MRCKB_HUMAN		Kd	5.60	CHEMBL
Citron Rho-interacting kinase	Kinase	O14578	CTRO_HUMAN		Kd	5.74	CHEMBL
AarF domain-containing protein kinase 4	Kinase	Q96D53	COQ8B_HUMAN		Kd	5.77	CHEMBL
Serine/threonine-protein kinase SIK1	Kinase	P57059	SIK1_HUMAN		Kd	5.72	CHEMBL
Tyrosine-protein kinase Srms	Kinase	Q9H3Y6	SRMS_HUMAN		Kd	5.72	CHEMBL
Dual specificity testis-specific protein kinase 1	Kinase	Q15569	TESK1_HUMAN		Kd	5.43	CHEMBL
Ephrin type-A receptor 1	Kinase	P21709	EPHA1_HUMAN	INHIBITOR	Kd	6.64	CHEMBL
Mitogen-activated protein kinase 6	Kinase	Q16659	MK06_HUMAN		Kd	5.82	CHEMBL
Fibroblast growth factor receptor 4	Kinase	P22455	FGFR4_HUMAN		Kd	5.64	CHEMBL
Ribosomal protein S6 kinase alpha-1	Kinase	Q15418	KS6A1_HUMAN		Kd	6.40	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2	Kinase	Q12851	M4K2_HUMAN		Kd	5.80	CHEMBL
Misshapen-like kinase 1	Kinase	Q8N4C8	MINK1_HUMAN		Kd	5.47	CHEMBL
Interleukin-1 receptor-associated kinase 4	Kinase	Q9NWZ3	IRAK4_HUMAN		Kd	7.12	CHEMBL
Ephrin type-B receptor 6	Kinase	O15197	EPHB6_HUMAN	INHIBITOR	Kd	7.12	CHEMBL
Hormonally up-regulated neu tumor-associated kinase	Kinase	P57058	HUNK_HUMAN		Kd	5.39	CHEMBL
Interleukin-1 receptor-associated kinase 1	Kinase	P51617	IRAK1_HUMAN		Kd	5.92	CHEMBL
Serine/threonine-protein kinase ULK3	Kinase	Q6PHR2	ULK3_HUMAN		Kd	5.19	CHEMBL
Mitogen-activated protein kinase kinase kinase 19	Kinase	Q56UN5	M3K19_HUMAN		Kd	6.01	CHEMBL
Receptor-interacting serine/threonine-protein kinase 4	Kinase	P57078	RIPK4_HUMAN		Kd	6.21	CHEMBL
Serine/threonine-protein kinase 35	Kinase	Q8TDR2	STK35_HUMAN		Kd	7.25	CHEMBL
Receptor tyrosine-protein kinase erbB-3	Kinase	P21860	ERBB3_HUMAN	INHIBITOR	Kd	6.80	CHEMBL
Serine/threonine-protein kinase SIK3	Kinase	Q9Y2K2	SIK3_HUMAN		Kd	5.41	CHEMBL
Bone morphogenetic protein receptor type-1B	Kinase	O00238	BMR1B_HUMAN		Kd	6.62	CHEMBL
Serine/threonine-protein kinase 32A	Kinase	Q8WU08	ST32A_HUMAN		Kd	5.30	CHEMBL
Macrophage-stimulating protein receptor	Kinase	Q04912	RON_HUMAN		IC50	5.47	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5	Kinase	Q13163	MP2K5_HUMAN		Kd	7.31	CHEMBL
ATP-binding cassette sub-family G member 2	Transporter	Q9UNQ0	ABCG2_HUMAN		IC50	6.70	CHEMBL
Platelet-derived growth factor receptor beta	Kinase	P09619	PGFRB_HUMAN		Kd	7.06	CHEMBL
Tubulin alpha-1A chain	Structural		TBA1A_RAT		Kd	6.32	CHEMBL

External reference:

ID	Source
4030726	VUID
N0000182736	NUI
D06407	KEGG_DRUG
4030726	VANDF
C1121849	UMLSCUI
CHEBI:49960	CHEBI
ZD6	PDB_CHEM_ID
CHEMBL24828	ChEMBL_ID
DB05294	DRUGBANK_ID
C452423	MESH_SUPPLEMENTAL_RECORD_UI
5717	IUPHAR_LIGAND_ID
8365	INN_ID
YO460OQ37K	UNII
3081361	PUBCHEM_CID
1098413	RXNORM
181099	MMSL
189346	MMSL
27846	MMSL
d07761	MMSL
013703	NDDF
418260004	SNOMEDCT_US
418520004	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
CAPRELSA	HUMAN PRESCRIPTION DRUG LABEL	1	58468-7820	TABLET, FILM COATED	100 mg	ORAL	NDA	32 sections
CAPRELSA	HUMAN PRESCRIPTION DRUG LABEL	1	58468-7820	TABLET, FILM COATED	100 mg	ORAL	NDA	32 sections
CAPRELSA	HUMAN PRESCRIPTION DRUG LABEL	1	58468-7820	TABLET, FILM COATED	100 mg	ORAL	NDA	32 sections
CAPRELSA	HUMAN PRESCRIPTION DRUG LABEL	1	58468-7840	TABLET, FILM COATED	300 mg	ORAL	NDA	32 sections
CAPRELSA	HUMAN PRESCRIPTION DRUG LABEL	1	58468-7840	TABLET, FILM COATED	300 mg	ORAL	NDA	32 sections
CAPRELSA	HUMAN PRESCRIPTION DRUG LABEL	1	58468-7840	TABLET, FILM COATED	300 mg	ORAL	NDA	32 sections
CAPRELSA	HUMAN PRESCRIPTION DRUG LABEL	1	58468-7860	TABLET, FILM COATED	300 mg	ORAL	UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE	4 sections